ARTICLE | Clinical News
Sapacitabine: Additional Phase II data
June 4, 2012 7:00 AM UTC
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Product: Sapacitabine ( CYC682) Business: Cancer Molecular target: D...